10-Q: Hims & Hers Reports Strong Q3 Growth, Achieves Profitability and Releases Valuation Allowance

Hims & Hers Health, Inc. reports a profitable third quarter with significant revenue growth and the release of a valuation allowance on deferred tax assets.

Summary

• Hims & Hers Health, Inc. reported a profitable third quarter, with net income of $75.6 million, a significant improvement compared to a net loss of $7.6 million in the same quarter of the previous year.
• The company's revenue reached $401.6 million, a 77% increase year-over-year, driven by both online and wholesale channels.
• Online revenue grew by 79% to $392.6 million, while wholesale revenue increased by 28% to $9.0 million.
• The number of subscribers grew by 44% to 2.0 million, and the monthly online revenue per average subscriber increased by 24% to $67.
• The average order value (AOV) also saw a substantial increase of 48% to $147.
• The company released a valuation allowance on its domestic deferred tax assets, resulting in a one-time income tax benefit of $60.8 million.
• Adjusted EBITDA for the quarter was $51.1 million, compared to $12.3 million in the same period last year.
• The company repurchased 1.9 million shares of Class A common stock for $30.0 million under its 2024 share repurchase program.
• Hims & Hers completed the acquisition of MedisourceRx, a 503B compounding outsourcing facility, for $31.0 million, including cash and stock consideration.

Sentiment

Score: 9

Explanation: The document presents a very positive outlook with strong financial results, significant growth metrics, and strategic acquisitions. The company's achievement of profitability and the release of the valuation allowance are major positive developments. The only minor negatives are the increased expenses, which are expected for a growth company.

Positives

• The company achieved profitability in Q3 2024, demonstrating a significant improvement in financial performance.
• Revenue growth was strong across both online and wholesale channels, indicating a diversified revenue stream.
• The increase in subscribers, monthly revenue per subscriber, and average order value suggests strong customer engagement and spending.
• The release of the valuation allowance on deferred tax assets resulted in a substantial one-time income tax benefit.
• The acquisition of MedisourceRx is expected to enhance the company's compounding capabilities and market presence.
• The company's share repurchase program demonstrates confidence in its future prospects and commitment to shareholder value.

Negatives

• Gross margin decreased slightly from 83% to 79% in the three months ended September 30, 2024, compared to the same period in 2023, primarily due to the addition of newer offerings.
• Marketing expenses increased by 57% year-over-year, reflecting the company's continued investment in customer acquisition.
• Operations and support expenses increased by 50% year-over-year, driven by increased employee compensation and fulfillment costs.
• Technology and development expenses increased by 72% year-over-year, reflecting the company's continued investment in its platform and new offerings.

Risks

• The company's future performance depends on its ability to attract new customers and retain existing ones.
• Changes in laws and regulations could impact the company's ability to market its products and services.
• The company faces intense competition from other healthcare providers, retailers, and technology companies.
• The company's brand is integral to its success, and any failure to maintain or enhance it could harm its business.
• The company relies on relationships with Affiliated Medical Groups and Pharmacies, and any disruption could adversely affect its operations.
• The company's pharmacy business subjects it to additional healthcare laws and regulations.
• Security breaches or loss of data could compromise sensitive information and expose the company to liability.
• The company may require additional capital to support its growth, which may not be available on acceptable terms.
• The dual-class stock structure concentrates voting power with the CEO, limiting investors' influence.
• The market price of the company's Class A common stock may be volatile.

Future Outlook

The company expects to continue to invest in its manufacturing, fulfillment, and operating capabilities, including its Affiliated Pharmacies and warehousing facilities, with the goal of fulfilling nearly all of its pharmaceutical and over-the-counter customer orders through affiliated and internal fulfillment capabilities. Additionally, the company expects to continue to make significant investments in marketing to acquire new customers and in product offerings and customer experience. The company may continue to pursue opportunities to acquire or invest in complementary businesses, services, and technologies, including intellectual property rights.

Industry Context

The company's strong performance reflects the growing demand for telehealth services and the increasing adoption of digital health solutions. The company's expansion into new specialties and its focus on customer experience position it well to compete in the evolving healthcare landscape. The acquisition of MedisourceRx is a strategic move to enhance its compounding capabilities and control over its supply chain.

Comparison to Industry Standards

• Hims & Hers' revenue growth of 77% year-over-year significantly outpaces the average growth rate of the telehealth industry, which is estimated to be around 20-30% annually.
• The company's subscriber growth of 44% also exceeds the industry average, indicating strong customer acquisition and retention.
• The increase in AOV to $147 suggests that Hims & Hers is successfully upselling its products and services, which is a key differentiator compared to competitors that focus solely on low-cost offerings.
• Compared to Teladoc, a major player in the telehealth space, Hims & Hers is demonstrating faster revenue growth and a more diversified business model with its focus on both online and wholesale channels.
• The acquisition of MedisourceRx is a strategic move that sets Hims & Hers apart from many of its competitors, giving it greater control over its supply chain and compounding capabilities, similar to Amazon Pharmacy's approach to vertical integration.
• The company's Adjusted EBITDA margin of 13% is a significant improvement compared to previous periods and indicates a path towards sustainable profitability, which is a key concern for many telehealth companies.

Related Party Transactions

• The company recorded $1.1 million and $1.0 million within operating expenses for payments made to Vouched, a related-party company, for the three months ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and share repurchase program.
• Employees may benefit from the company's growth and expansion.
• Customers will benefit from the company's continued investment in its platform and offerings.
• Suppliers and partners may benefit from the company's increased scale and market presence.

Next Steps

• The company intends to continue to invest in its manufacturing, fulfillment, and operating capabilities.
• The company expects to continue to make significant investments in marketing to acquire new customers.
• The company plans to continue to invest in product offerings and customer experience.
• The company may continue to pursue opportunities to acquire or invest in complementary businesses, services, and technologies.

Key Dates

Keywords

telehealth, pharmacy, compounding, subscription, healthcare, e-commerce, digital health, direct-to-consumer, GLP-1, weight loss